|
DR. MICHAEL PEAT APPOINTED TO BOARD OF DIRECTORS OF WPCI.
SCOTTSBLUFF, NE, March 29, 2001 – WPCI (Western Pathology
Consultants, Inc.) announced the appointment of Dr. Michael Peat to its
Board of Directors.
Dr. Peat has served as President of the Substance Abuse Testing Division and
Executive Vice President of Toxicology for LabOne, Inc as well as Vice President of
Toxicology for Roche Biomedical Laboratories and CompuChem Laboratories,
Inc. A graduate of Oxford Polytechnic, Oxford, England and the Department of
Biochemical Pharmacology and Toxicology, University of Utah, Dr. Peat is
well renowned in the workplace drug and alcohol testing industry and has
held various appointments in the American Academy of Forensic Sciences and
the Society of Forensic Toxicologists.
“Dr. Peat testified at the original National Transportation Safety Board
hearing that was instrumental in prompting the Department of Transportation
to require drug testing for the companies they regulate,” according to WPCI President and
CEO, Bill Stopperan. He has held professional honors in the American
Academy of Forensic Sciences and Toxicology, American board of Forensic
Toxicology, Society of Forensic Toxicologists, California Association of
Toxicologists, College of American Pathologists, Department of Health and
Human Services, American College of Occupational and Environmental Medicine,
and the American Society of Mass Spectrometry.
“With the growth that we expect over the course of the next couple years,
Dr. Peat is a welcomed addition to help in the strategic guidance of WPCI,”
Stopperan said. “He will be able to provide us with great insight as to
where the future of drug testing will be.”
WPCI is one of the nation’s leading drug and alcohol testing program
administrators with several Medical Review Officers on staff and over 6,000
contracted specimen collection centers. WPCI provides drug testing services
to more than 2,500 clients located throughout the United States, Puerto
Rico, and the Virgin Islands. WPCI experienced a 37% growth in revenues from
1999 to 2000 and after 2 months into 2001, they are 25% above last year’s
first two month’s revenue.
Forward-looking statements in this release are made pursuant
to the “safe harbor” provisions of the Private Securities Litigation Reform
Act of 1995. Investors are cautioned that such forward-looking statements
involve risk and uncertainties, including without limitation, continued
acceptance of the Company’s products, increased levels of competition for
the Company, new products and technological changes, the Company’s
dependence on third-party suppliers, intellectual property rights and other
risks detailed from time to time in the Company’s periodic reports filed
with the Securities and Exchange Commission.
|
